Ascend Laboratories has received FDA approval for the generic combination drug ibuprofen and famotidine, placing it in direct competition with branded products and anticipating their share of the OTC prescription-drug clash market. The launch of this new formulation is expected to capitalize on the growing demand for cost-effective ulcer prophylaxis alongside pain relief.